Saia, Inc. (SAIA)
NASDAQ: SAIA · Real-Time Price · USD
293.09
-9.15 (-3.03%)
At close: Aug 1, 2025, 4:00 PM
291.64
-1.45 (-0.49%)
After-hours: Aug 1, 2025, 7:54 PM EDT
Revance Therapeutics Stock Forecast
Stock Price Forecast
The 18 analysts that cover Revance Therapeutics stock have a consensus rating of "Buy" and an average price target of $374.06, which forecasts a 27.63% increase in the stock price over the next year. The lowest target is $285 and the highest is $515.
Price Target: $374.06 (+27.63%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Revance Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 6 | 5 | 6 | 5 |
| Buy | 7 | 7 | 6 | 6 | 6 | 6 |
| Hold | 5 | 5 | 6 | 7 | 6 | 7 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 18 | 18 | 18 | 18 | 18 | 18 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Stephens & Co. | Stephens & Co. | Hold Maintains $274 → $300 | Hold | Maintains | $274 → $300 | +2.36% | Jul 29, 2025 |
| Citigroup | Citigroup | Strong Buy Maintains $350 → $393 | Strong Buy | Maintains | $350 → $393 | +34.09% | Jul 28, 2025 |
| JP Morgan | JP Morgan | Buy Maintains $295 → $380 | Buy | Maintains | $295 → $380 | +29.65% | Jul 28, 2025 |
| Wells Fargo | Wells Fargo | Hold Maintains $290 → $365 | Hold | Maintains | $290 → $365 | +24.54% | Jul 28, 2025 |
| Barclays | Barclays | Buy Maintains $315 → $350 | Buy | Maintains | $315 → $350 | +19.42% | Jul 28, 2025 |
Financial Forecast
Revenue This Year
3.28B
from 3.21B
Increased by 2.12%
Revenue Next Year
3.50B
from 3.28B
Increased by 6.90%
EPS This Year
9.31
from 13.51
Decreased by -31.07%
EPS Next Year
12.24
from 9.31
Increased by 31.42%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 3.5B | 3.7B | 4.2B | ||
| Avg | 3.3B | 3.5B | 3.8B | ||
| Low | 3.1B | 3.2B | 3.5B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 8.4% | 13.7% | 19.0% | ||
| Avg | 2.1% | 6.9% | 8.4% | ||
| Low | -4.3% | -2.0% | -1.1% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 11.47 | 14.60 | 18.26 | ||
| Avg | 9.31 | 12.24 | 15.33 | ||
| Low | 8.08 | 10.29 | 13.03 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -15.1% | 56.7% | 49.2% | ||
| Avg | -31.1% | 31.4% | 25.3% | ||
| Low | -40.2% | 10.5% | 6.5% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.